治疗性HIV-1疫苗HIVAX可降低ART下患者的全身免疫激活与潜伏感染标志物
该研究评估了在ART病毒抑制状态下接种复制缺陷型HIV-1治疗性疫苗HIVAX对慢性免疫激活和潜伏感染的影响。接种后第16周,CD8+HLA-DR+CD38+T细胞百分比接近健康对照水平,促炎细胞因子和外周α4β7+浆细胞样树突状细胞减少,HIV-1 DNA和2-LTR环水平降低。研究提示HIVAX可影响HIV-1潜伏库并减少病毒复制。
要点
- HIVAX接种后第16周CD8+HLA-DR+CD38+T细胞百分比接近健康对照。
- 接种后促炎细胞因子及外周α4β7+浆细胞样树突状细胞减少。
- 接种后HIV-1 DNA与2-LTR环水平降低,提示影响潜伏与复制。
核心结论
- 在长期抗病毒抑制的HIV感染者中接种HIVAX可降低免疫激活/慢性炎症和潜伏感染。
研究设计与样本
- 研究为治疗性HIV疫苗HIVAX的临床试验,受试者为ART下病毒抑制的HIV感染者,注册号NCT01428596。
主要发现
- 接种后第16周,CD8+HLA-DR+CD38+T细胞百分比接近健康对照水平。
- 免疫激活降低伴随促炎细胞因子和外周α4β7+浆细胞样树突状细胞减少。
- 接种后第16周HIV-1 DNA和2-LTR环水平均降低。
- 免疫激活/慢性炎症降低的同时,表达PD-1和TIM-3的记忆CD4+T细胞百分比增加。
- HIV-1 Gag特异性CD4+T细胞中多种参与免疫激活、T细胞激活和抗病毒反应调控的基因表达增加。
临床怎么用
- 该结果提示治疗性疫苗HIVAX可能作为ART下HIV感染者的辅助免疫干预策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
HIV infection is characterized by chronic immune activation and the establishment of a pool of latently infected cells. Antiretroviral therapy (ART) can suppress viral load to undetectable levels in peripheral blood by standard measure, however immune activation/chronic inflammation and latent infection persist and affect quality of life. We have now shown that a novel therapeutic HIV vaccine consisting of replication-defective HIV (HIVAX), given in the context of viral suppression under ART, can reduce both immune activation/chronic inflammation and latent infection. Immune activation, as measured by percent of CD8 + HLA-DR + CD38 + T cells, approached levels of healthy controls at week 16 following vaccination. Reduced immune activation was accompanied by a reduction in pro-inflammatory cytokines and peripheral α4β7 + plasmacytoid DC (a marker of mucosal immune activation). Levels of both HIV-1 DNA and 2-LTR circles were reduced at week 16 following vaccination, suggesting HIVAX can impact HIV-1 latency and reduce viral replication. Surprisingly, reduced immune activation/chronic inflammation was accompanied by an increase in the percent of memory CD4 + T cells expressing markers PD-1 and TIM-3. In addition, evaluation of HIV-1 Gag-specific CD4 + T cells for expression of 96 T cell related genes pre- and post-therapy revealed increased expression of a number of genes involved in the regulation of immune activation, T cell activation, and antiviral responses. Overall this study provides evidence that vaccination with HIVAX in subjects under long term antiviral suppression can reduce immune activation/chronic inflammation and latent infection (Clinicaltrials.gov, identifier NCT01428596).
引用
- Pallikkuth S, Bolivar H, Fletcher MA, et al. A therapeutic HIV-1 vaccine reduces markers of systemic immune activation and latent infection in patients under highly active antiretroviral therapy. Vaccine. 2020. PMID: 32387010. doi:10.1016/j.vaccine.2020.04.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。